» Articles » PMID: 35052950

Antifungal Activity of Natural Compounds Vs. Spp.: A Mixture of Cinnamaldehyde and Eugenol Shows Promising In Vitro Results

Overview
Specialty Pharmacology
Date 2022 Jan 21
PMID 35052950
Authors
Affiliations
Soon will be listed here.
Abstract

Methods: Fungistatic activity was evaluated using the disk diffusion method. For fungicidal activity, microdilution and time-kill curve protocols were set up. The checkerboard method was chosen to evaluate a possible synergistic effect of these compounds when mixed.

Results: Cinnamaldehyde and eugenol gave the best results, inhibiting all the strains and showing a highly additive effect (FICI 0.625). The cinnamaldehyde inhibition zone (IZ), MIC, and MFC means were 69 mm, 50.05 mg/L, and 109.26 mg/L respectively. Cinnamaldehyde led to the total loss of viable cells within 4 h. Eugenol IZ, MIC, and MFC means were 35.2 mm, 455.42 mg/L, and 690.09 mg/L, respectively. Eugenol led to the total loss of viable fungal cells within 1 h. Treatment with α-pinene inhibited 88.9% of strains, with an IZ mean of 21.2 mm, a MIC mean of 195.41 mg/L, and a MFC mean of 251.27 mg/L; this compound led to the total loss of viable fungal cells only after 24 h. Limonene inhibited only 33.3% of the tested strains and eucalyptol did not produce an inhibition halo, so these compounds were not tested further.

Conclusions: These characteristics, together with the well-known safety of cinnamaldehyde and eugenol for human use, make these two natural compounds the perfect candidates for the treatment of candidiasis. This was a pilot study, the purpose of which was to evaluate the best composition of a mixture to be used against intestinal and vulvovaginal candidiasis; in vivo studies are needed to confirm these very encouraging results.

Citing Articles

Clove Essential Oil as a Source of Antitumoral Compounds Capable of Crossing the Blood-Brain Barrier: A Focus on the Effects of β-Caryophyllene and Eugenol in a Glioblastoma Cell Line.

Spigarelli R, Spisni E, Magalhaes M, Cabral C, Goncalves A, Saracino I Int J Mol Sci. 2025; 26(1.

PMID: 39796096 PMC: 11720353. DOI: 10.3390/ijms26010238.


Bioactive Potential of Chitosan-Oleic Acid Nanoparticles Loaded with Lemon Peel Essential Oil for Topical Treatment of Vulvovaginal Candidiasis.

Ibrahim F, Shalaby E, Abdelhameed M, El-Akad R, Ahmed K, Abdel-Aziz M Molecules. 2024; 29(23).

PMID: 39683923 PMC: 11643761. DOI: 10.3390/molecules29235766.


Exploring the Antibiofilm Effect of Sertraline in Synergy with Essential Oil to Counteract Species.

Barbarossa A, Rosato A, Carrieri A, Fumarola L, Tardugno R, Corbo F Pharmaceuticals (Basel). 2024; 17(9).

PMID: 39338275 PMC: 11435152. DOI: 10.3390/ph17091109.


Design, synthesis, docking studies and bioactivity evaluation of 1,2,3-triazole eugenol derivatives.

de Sousa Cutrim T, Barcelos F, Meireles L, Gazolla P, Lima A, Ricardo Teixeira R Future Med Chem. 2024; 16(18):1883-1897.

PMID: 39157870 PMC: 11486170. DOI: 10.1080/17568919.2024.2385292.


Encapsulation of Cinnamaldehyde and Vanillin as a Strategy to Increase Their Antimicrobial Activity.

Sepulveda F, Puente-Diaz L, Ortiz-Viedma J, Rodriguez A, Char C Foods. 2024; 13(13).

PMID: 38998538 PMC: 11241658. DOI: 10.3390/foods13132032.


References
1.
Low C, Rotstein C . Emerging fungal infections in immunocompromised patients. F1000 Med Rep. 2011; 3:14. PMC: 3155160. DOI: 10.3410/M3-14. View

2.
Sobel J . Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 1985; 152(7 Pt 2):924-35. DOI: 10.1016/s0002-9378(85)80003-x. View

3.
Yen D, Cheung J, Scheerens H, Poulet F, Mcclanahan T, McKenzie B . IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006; 116(5):1310-6. PMC: 1451201. DOI: 10.1172/JCI21404. View

4.
Kaur S, Mishra P . Dimorphism-associated changes in plasma membrane H(+)-ATPase activity of Candida albicans. Arch Microbiol. 1991; 156(5):412-5. DOI: 10.1007/BF00248719. View

5.
Lass-Florl C . The changing face of epidemiology of invasive fungal disease in Europe. Mycoses. 2009; 52(3):197-205. DOI: 10.1111/j.1439-0507.2009.01691.x. View